In Vitro + In Vivo Cancer Biology Services
SRI Biosciences offers clients several in vitro cancer assays to help determine the efficacy, mechanism of action, and toxicity of their compounds. With in vitro cancer research, we employ numerous human cell lines derived from cancers of the lung, stomach, colon, breast, prostate, ovary, liver, skin, leukemia, lymphoma, and more. Whenever possible, SRI obtains cell lines from clients to decrease nonreproducible results due to variants arising from multiple passages of cells.
If the client desires a specific cell line not in our library, we will determine its availability from sources such as the American Type Culture Collection (ATCC).
SRI offers these in vitro services:
-
Cell proliferation and growth inhibition assays (tumor and endothelial cells)
-
Apoptosis assays (tumor and endothelial cells)
-
Cell cycle and apoptosis analysis using flow cytometry
-
Migration and invasion assays (Matrigel® and fibrin gel)
-
Receptor binding and activity assays (ER, PR, AR, PPAR, etc.)
-
ELISA, Western blots on treated animal tissue and cell lysates for enzymes, cytokines and other protein targets
-
Zymogels for protease activity (MMPs, etc.)
-
RNA isolation, PCR, RT-PCR and SuperArray®
-
Biochemical assays for target effectiveness on treated animal tissues
-
Custom in vitro assays
Clients often have a number of compounds of interest and need in vitro efficacy data to select the best compounds with which to move forward. In addition to efficacy assays, SRI offers toxicity assays to estimate the absorption, metabolism, and toxicity of the compounds of interest. The results from in vitro cancer biology assessment can be used to select the best lead candidates and design the appropriate in vivo efficacy experiments.
